Medivir appoints Vice President, Research & Development Projects
Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, is pleased to announce the appointment of Charlotte Edenius to the new position of Vice President, Research & Development Projects, effective 1 November 2010. This newly created position, with responsibility for Medivir’s project portfolio, marks another step in the direction of strategically enhancing Medivir’s R&D organisation, and accordingly, Charlotte will become a member of the company’s management.
Charlotte holds a medical degree and has a Ph.D. from the Karolinska Institute. She joins Medivir from a position as Senior Vice President and Chief Scientific Officer of Swedish pharmaceutical company Orexo AB. Charlotte’s previous positions also include being Vice President and Chief Scientific Officer of Biolipox AB in 2001-2007 and various executive positions in Experimental Medicine, Clinical R&D AstraZeneca, at Södertälje, Sweden in 1995-2001
“I’m very pleased to bring Charlotte Edenius into Medivir in this position as Vice President, Research & Development Projects where she will bring key competence to our projects. Her very extensive and in-depth knowledge of the life sciences sector, from the research side, preclinical and clinical development, will also reinforce our strategic endeavor to become a profitable medium-sized company within a five-year period, with high growth and a focus on infectious diseases,” commented Bertil Samuelsson, CSO, Research & Development.
For more information, please contact
Rein Piir, CFO and a VP, IR, +46 (0)70 853 7292.
Medivir is a research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world-class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product, an innovative treatment for cold sores.
Xerese™/Xerclear® is a treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and by prescription sold by Meda in North America. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.
Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.
For more information about Medivir, please visit the Company’s website: www.medivir.se